CG Oncology, Inc.

For the period ended Jun 30, 2025. Filed Aug 8, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 8, 2025

CGON$74.74-1.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

	June 30,	December 31,
	2025	2024
Assets · (unaudited)
Current assets:
Cash and cash equivalents	$14,624	$257,068
Marketable securities	646,428	484,930
Prepaid expenses and other current assets	11,416	11,431
Accounts receivable - other	562	781
Total current assets	673,030	754,210
Property and equipment, net	253	272
Note receivable, net	26,675	—
Operating lease right-of-use assets	965	221
Other assets	522	94
Total assets	$701,445	$754,797
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$7,125	$6,517
Operating lease liabilities, current portion	288	186
Accrued expenses and other current liabilities	22,968	14,665
Total current liabilities	30,381	21,368
Operating lease liabilities, net of current portion	706	52
Total liabilities	31,087	21,420
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, $0.0001 par value per share; 700,000,000 and 700,000,000 shares authorized as of June 30, 2025 and December 31, 2024, respectively; 76,231,859 and 76,154,783 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively	8	8
Additional paid-in capital	964,209	951,350
Accumulated deficit	(293,859)	(217,981)
Total stockholders' equity	670,358	733,377
Total liabilities and stockholders' equity	$701,445	$754,797

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.